患有宏类过敏的患者中fidaxomicin过敏的发生率:一个大型数据库分析

相关实验视频

Updated: May 12, 2026

07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.7K

Chia-Yu Chiu¹, Daniel B Chastain², Madison E Salam³

¹Department of Medicine, Division of Infectious Diseases, University of Colorado, Aurora, Colorado, USA.

Antimicrobial agents and chemotherapy

|March 4, 2025

概括

患有宏类过敏的患者,如阿齐思罗米,克拉里思罗米或红色素,面临着菲达克索米过敏的可能性增加. 这种风险,包括像过敏反应这样的严重反应,在之前暴露于宏化物的一年内是最高的.

科学领域:

药理学药理学是指药理学的学科.
过敏和免疫学过敏和免疫学
传染性疾病传染性疾病

背景情况:

菲达克索米辛是一种宏环抗生素,用于治疗Clostridioides difficile感染.
宏类抗生素具有共同的化学结构,这引发了对交叉反应性的担忧.
之前关于现有宏类过敏患者的菲达克索米辛交叉反应性的数据有限.

研究的目的:

调查以前的类过敏和fidaxomicin过敏的风险之间的关联.
量化患有对特定类素 (亚齐胺素,克拉里胺素,红胺素) 过敏的患者的菲达克索米辛过敏的几率和绝对风险.
评估非菲达克索米辛宏类过敏和对菲达克索米辛的严重过敏反应之间的时间关系.

主要方法:

对患者数据的回顾性分析.
在以前有或没有类素过敏的患者之间比较fidaxomicin过敏率.
根据特定的类过敏,计算fidaxomicin过敏的几率比和绝对风险.

主要成果:

患有阿齐思罗米辛,克拉里思罗米辛和红色素过敏的患者患有菲达克索米辛过敏的几率显著更高 (分别为OR 2.31,8.37,1.58).
对于先前患有阿齐思罗米辛,克拉里斯罗米辛和红素过敏的患者,菲达克索米辛过敏的绝对风险分别为0.033,0.01和0.039.
在非菲达克索米辛宏化物过敏后的一年内,厌氧和血管风险增加.

结论:

菲达克索米辛可能在有史以来宏类过敏的患者中表现出交叉反应性.
临床医生在给已知过敏于亚齐胺素,克拉里胺素或红胺素的患者开药时应谨慎.
可能需要进一步的研究来阐明交叉反应的确切机制,并完善风险评估策略.

关键词:

亚齐特罗米辛是一种亚齐特罗米辛.克拉里斯罗米辛是什么意思克拉里斯罗米辛药物过敏症药物过敏症红色氨酸是什么红色氨酸这就是fidaxomicin.

相关概念视频

01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

01:30

Drug Toxicity: Allergic Reactions

01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...

01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...